Fanfan Li

No. 678 Furong Road, Anhui Province
Hefei, 230601, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Thyroid-specific symptom burden rather than psychological distress following thermal ablation versus open surgery for low-risk thyroid cancer: a 24-month propensity score-matched patient-reported outcome study.

Thyroid-specific symptom burden rather than psychological distress following thermal ablation versus open surgery for low-risk thyroid cancer: a 24-month propensity score-matched patient-reported outcome study.

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Published: June 02, 2026

Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.

Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.

Journal: Biomolecules & biomedicine

Published: April 23, 2026

Efficacy and Safety of Dalpiciclib in HR-Positive Advanced Breast Cancer: A Two-Center Retrospective Study.

Efficacy and Safety of Dalpiciclib in HR-Positive Advanced Breast Cancer: A Two-Center Retrospective Study.

Journal: Cancers

Published: January 15, 2026

Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.

Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.

Journal: Cancer communications (London, England)

Published: December 09, 2025

Identifying research gaps in PIK3CA-mutant breast cancer: a bibliometric analysis of evolving trends and clinical applications.

Identifying research gaps in PIK3CA-mutant breast cancer: a bibliometric analysis of evolving trends and clinical applications.

Journal: Translational cancer research

Published: December 01, 2025

Multifunctional metal organic frameworks for enhancing mild-temperature photothermal therapy via inhibiting HSP expression.

Multifunctional metal organic frameworks for enhancing mild-temperature photothermal therapy via inhibiting HSP expression.

Journal: Journal of biomaterials applications

Published: December 01, 2025

Prognostic Value of Phosphatidylinositol-3 Kinase p110 α Protein Expression in Patients with Stage I-III Invasive Breast Cancer.

Prognostic Value of Phosphatidylinositol-3 Kinase p110 α Protein Expression in Patients with Stage I-III Invasive Breast Cancer.

Journal: Cancers

Published: November 11, 2025

PRSS23 functions downstream of ZEB1 to promote esophageal squamous cell carcinoma progression by driving M2 polarization of tumor associated macrophages.

PRSS23 functions downstream of ZEB1 to promote esophageal squamous cell carcinoma progression by driving M2 polarization of tumor associated macrophages.

Journal: Molecular and cellular biochemistry

Published: August 01, 2025

Bioequivalence of two doxorubicin liposome formulations (LY01612 and Caelyx) using free and encapsulated doxorubicin concentrations in Chinese patients with advanced breast cancer.

Bioequivalence of two doxorubicin liposome formulations (LY01612 and Caelyx) using free and encapsulated doxorubicin concentrations in Chinese patients with advanced breast cancer.

Journal: International journal of clinical pharmacology and therapeutics

Published: June 02, 2025

High expression of G3BP1 is associated with poor prognosis in breast invasive carcinoma.

High expression of G3BP1 is associated with poor prognosis in breast invasive carcinoma.

Journal: Oncology letters

Published: May 14, 2025

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 11, 2025

Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02).

Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02).

Journal: Signal transduction and targeted therapy

Published: April 07, 2025

Showing 1-12 of 31

Last Updated: 09/26/2026